STOCK TITAN

QuidelOrtho Corporation (QDEL) DEF 14A Filings

QDEL NASDAQ

Here are the DEF 14A proxy statements from QuidelOrtho Corporation (QDEL) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow QDEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QDEL filings page.

Rhea-AI Summary

QuidelOrtho Corporation has issued its definitive proxy for the 2026 virtual annual meeting on June 16, 2026. Stockholders will vote on electing 10 directors for one-year terms, an advisory Say‑on‑Pay resolution on executive compensation, and ratifying KPMG as independent auditor for the fiscal year ending January 3, 2027.

The company highlights strong 2025 execution as it shifts from COVID‑driven volatility toward a more durable diagnostics mix, with revenue of $2.73 billion, including $2.33 billion from non‑respiratory products and $402 million from respiratory products. Adjusted EBITDA margin reached 22% as GAAP operating expenses fell 5% through cost‑savings initiatives.

The Board emphasizes robust governance, with an independent Chair, majority‑independent Board and fully independent committees, annual director elections, and stock ownership requirements for directors and executives. It recommends voting FOR all director nominees, FOR the Say‑on‑Pay proposal, and FOR ratifying KPMG.